Macular degeneration and macular dystrophy are eye conditions affecting the center of the retina. Although they share overlapping symptoms, their root causes and treatments differ. Macular ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Macular degeneration affects the macula, a part of the retina at the back of the eye. Doctors often refer to it as age-related macular degeneration (AMD). There are two types of macular degeneration: ...

Age-related macular degeneration, the leading cause of vision loss and blindness for Americans 65 and older, is a progressive disease affecting central vision. Over time, faces, book pages and ...

Myopia, or nearsightedness, is a common eye condition. More than 40% of Americans can't see clearly at a distance because their eye is longer than normal. Usually myopia doesn't cause any problems ...

Geographic atrophy (GA) is one of two kinds of advanced age-related macular degeneration (AMD). It’s an eye disease that damages cells in the central part of your retina called the macula. Late-stage ...

There are two types of macular degeneration: dry and wet. Dry age-related macular degeneration is the most common type — it happens when small deposits form under the retina, causing cells in the ...

Quitting smoking and getting regular eye exams may lower your risk of macular degeneration. Eating a Mediterranean diet can reduce your risk of advanced AMD by 41%. You can wear sunglasses that block ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...

Macular degeneration is the leading cause of vision loss in people older than 65. Smoking doubles your risk of macular degeneration compared to non-smokers. Your risk of the disease increases if you ...

The single most expensive drug for the Australian government today, costing more than A$400 million per year, is one called aflibercept. It stops the growth and “leakiness” of blood vessels, and is ...